BC
SYRE icon

BIT Capital’s Spyre Therapeutics SYRE Stock Holding History

BIT Capital’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,000
Closed -$13.2K – 176
2022
Q3 		$13.2K Hold
1,000
– – ﹤0.01% 140
2022
Q2 		$12.6K Hold
1,000
– – ﹤0.01% 111
2022
Q1 		$57.5K Hold
1,000
– – 0.01% 112
2021
Q4 		$119K Buy
+1,000
New +$158K 0.01% 111

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BIT Capital's SYRE Position: Q4 2022 in Review

BIT Capital sold out of Spyre Therapeutics (SYRE) in Q4 2022, closing a stake of 1,000 shares — an estimated $13.2K sold.

BIT Capital first reported a position in SYRE in Q4 2021 and held it in 4 quarters. The position peaked at $119K in Q4 2021. 50 funds tracked by Wall St. Rank hold SYRE as of Q4 2022.

  • BIT Capital reported no remaining Spyre Therapeutics position as of Q4 2022 after selling out during the quarter.
  • BIT Capital sold 1,000 Spyre Therapeutics shares in Q4 2022, an estimated $13.2K.
  • BIT Capital first reported a position in Spyre Therapeutics in Q4 2021 and held it in 4 quarters.
  • BIT Capital's Spyre Therapeutics position peaked at $119K in Q4 2021.
  • 50 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2022.

Based on BIT Capital's 13F filing for Q4 2022, filed 12 Feb 2025.